OnKure Therapeutics (OKUR) and Its Rivals Critical Contrast

OnKure Therapeutics (NASDAQ:OKUR) is one of 1,045 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare OnKure Therapeutics to related businesses based on the strength of its institutional ownership, risk, valuation, dividends, analyst recommendations, profitability and earnings.

Earnings and Valuation

This table compares OnKure Therapeutics and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
OnKure Therapeutics	N/A	-$77.39 million	-1.36
OnKure Therapeutics Competitors	$2.17 billion	$150.70 million	-5.38

OnKure Therapeutics’ competitors have higher revenue and earnings than OnKure Therapeutics. OnKure Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares OnKure Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-51.17%	-47.11%
OnKure Therapeutics Competitors	-3,610.73%	-267.68%	-30.94%

Risk & Volatility

OnKure Therapeutics has a beta of 0.21, suggesting that its stock price is 79% less volatile than the S&P 500. Comparatively, OnKure Therapeutics’ competitors have a beta of 1.00, suggesting that their average stock price is 0% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for OnKure Therapeutics and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	0	0	2	1	3.33
OnKure Therapeutics Competitors	7552	20789	48373	1185	2.55

OnKure Therapeutics presently has a consensus target price of $37.50, suggesting a potential upside of 125.90%. As a group, “Pharmaceutical preparations” companies have a potential upside of 74.41%. Given OnKure Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe OnKure Therapeutics is more favorable than its competitors.

Institutional & Insider Ownership

91.0% of OnKure Therapeutics shares are owned by institutional investors. Comparatively, 44.4% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 17.9% of OnKure Therapeutics shares are owned by company insiders. Comparatively, 13.8% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

OnKure Therapeutics beats its competitors on 9 of the 13 factors compared.

OnKure Therapeutics Company Profile

Reneo Pharmaceuticals Inc.is a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Inc.is based in SAN DIEGO.